Total Payments
$151,404
2019 Payments
$18,725
Companies
6
Transactions
19
Payment Breakdown by Category
Research$151,225 (99.9%)
Food & Beverage$178.81 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $151,225 | 8 | 99.9% |
| Food and Beverage | $178.81 | 11 | 0.1% |
Payments by Type
Research
$151,225
8 transactions
General
$178.81
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch Health US, LLC | $151,225 | 8 | $0 (2019) |
| Allergan Inc. | $54.23 | 4 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $46.14 | 3 | $0 (2018) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $35.25 | 2 | $0 (2018) |
| Johnson & Johnson Surgical Vision, Inc. | $27.18 | 1 | $0 (2017) |
| Aerie Pharmaceuticals, Inc. | $16.01 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $18,725 | 2 | Bausch Health US, LLC ($18,725) |
| 2018 | $132,585 | 11 | Bausch Health US, LLC ($132,500) |
| 2017 | $94.14 | 6 | Allergan Inc. ($36.93) |
All Payment Transactions
19 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/19/2019 | Bausch Health US, LLC | AZOPT (Drug) | — | Cash or cash equivalent | $8,725.00 | Research |
| Study: A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED, PARALLEL GROUP, MULTI-CENTER BIOEQUIVELENCE STUDY OF THE GENERIC BRINZOLAMIDE 1 OPHTHALMIC SUSPENSION COMPARED TO BRANDED BRINZOLAMIDE 1 OPHTHALMIC SUSPENSION AZOPT IN SUBJECTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION • Category: OPHTHALMOLOGY | ||||||
| 01/14/2019 | Bausch Health US, LLC | AZOPT (Drug) | — | Cash or cash equivalent | $10,000.00 | Research |
| Study: A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED, PARALLEL GROUP, MULTI-CENTER BIOEQUIVELENCE STUDY OF THE GENERIC BRINZOLAMIDE 1 OPHTHALMIC SUSPENSION COMPARED TO BRANDED BRINZOLAMIDE 1 OPHTHALMIC SUSPENSION AZOPT IN SUBJECTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION • Category: OPHTHALMOLOGY | ||||||
| 12/03/2018 | Bausch Health US, LLC | BRINZOLAMIDE (Drug) | — | Cash or cash equivalent | $10,000.00 | Research |
| Study: A Randomized, Double-Masked, Active-Controlled, Parallel Group, Multi-Center Bioequivalence Study of the Generic Brinzolamide 1 Ophthalmic Suspension Compared to Reference Listed Drug Azopt Brinzolamide Ophthalmic Suspension 1 in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension. • Category: OPHTHALMOLOGY | ||||||
| 11/13/2018 | Bausch & Lomb, a division of Bausch Health US, LLC | BTOD (Device), ULTRA | Food and Beverage | In-kind items and services | $18.19 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/01/2018 | Bausch Health US, LLC | BRINZOLAMIDE (Drug) | — | Cash or cash equivalent | $20,000.00 | Research |
| Study: A Randomized, Double-Masked, Active-Controlled, Parallel Group, Multi-Center Bioequivalence Study of the Generic Brinzolamide 1 Ophthalmic Suspension Compared to Reference Listed Drug Azopt Brinzolamide Ophthalmic Suspension 1 in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension. • Category: OPHTHALMOLOGY | ||||||
| 10/04/2018 | Bausch Health US, LLC | BRINZOLAMIDE (Drug) | — | Cash or cash equivalent | $10,000.00 | Research |
| Study: A Randomized, Double-Masked, Active-Controlled, Parallel Group, Multi-Center Bioequivalence Study of the Generic Brinzolamide 1 Ophthalmic Suspension Compared to Reference Listed Drug Azopt Brinzolamide Ophthalmic Suspension 1 in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension. • Category: OPHTHALMOLOGY | ||||||
| 09/04/2018 | Bausch Health US, LLC | BRINZOLAMIDE (Drug) | — | Cash or cash equivalent | $70,000.00 | Research |
| Study: A Randomized, Double-Masked, Active-Controlled, Parallel Group, Multi-Center Bioequivalence Study of the Generic Brinzolamide 1 Ophthalmic Suspension Compared to Reference Listed Drug Azopt Brinzolamide Ophthalmic Suspension 1 in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension. • Category: OPHTHALMOLOGY | ||||||
| 09/04/2018 | Allergan Inc. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $17.30 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/02/2018 | Bausch Health US, LLC | BRINZOLAMIDE (Drug) | — | Cash or cash equivalent | $20,000.00 | Research |
| Study: A Randomized, Double-Masked, Active-Controlled, Parallel Group, Multi-Center Bioequivalence Study of the Generic Brinzolamide 1 Ophthalmic Suspension Compared to Reference Listed Drug Azopt Brinzolamide Ophthalmic Suspension 1 in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension. • Category: OPHTHALMOLOGY | ||||||
| 06/18/2018 | Aerie Pharmaceuticals, Inc. | Rhopressa (Drug) | Food and Beverage | In-kind items and services | $16.01 | General |
| Category: Ophthalmology | ||||||
| 06/06/2018 | Bausch Health US, LLC | BRINZOLAMIDE (Drug) | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: A Randomized, Double-Masked, Active-Controlled, Parallel Group, Multi-Center Bioequivalence Study of the Generic Brinzolamide 1 Ophthalmic Suspension Compared to Reference Listed Drug Azopt Brinzolamide Ophthalmic Suspension 1 in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension. • Category: OPHTHALMOLOGY | ||||||
| 05/09/2018 | Bausch & Lomb, a division of Bausch Health US, LLC | VYZULTA (Drug) | Food and Beverage | In-kind items and services | $17.06 | General |
| Category: OPHTHALMOLOGY | ||||||
| 04/24/2018 | Novartis Pharmaceuticals Corporation | TRAVATAN Z (Drug) | Food and Beverage | In-kind items and services | $16.11 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/06/2017 | Johnson & Johnson Surgical Vision, Inc. | Tecnis iTec Preloaded Delivery System (Device) | Food and Beverage | In-kind items and services | $27.18 | General |
| Category: Optics | ||||||
| 10/31/2017 | Allergan Inc. | COMBIGAN (Drug) | Food and Beverage | In-kind items and services | $10.57 | General |
| Category: OPHTHALMOLOGY | ||||||
| 06/20/2017 | Allergan Inc. | COMBIGAN (Drug) | Food and Beverage | In-kind items and services | $13.28 | General |
| Category: OPHTHALMOLOGY | ||||||
| 04/04/2017 | Novartis Pharmaceuticals Corporation | TRAVATAN Z (Drug) | Food and Beverage | In-kind items and services | $12.07 | General |
| Category: OPHTHALMOLOGY | ||||||
| 03/21/2017 | Novartis Pharmaceuticals Corporation | DUREZOL (Drug), ILEVRO | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: OPHTHALMOLOGY | ||||||
| 02/13/2017 | Allergan Inc. | RESTASIS (Drug) | Food and Beverage | In-kind items and services | $13.08 | General |
| Category: DRY EYE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-Masked, Active-Controlled, Parallel Group, Multi-Center Bioequivalence Study of the Generic Brinzolamide 1 Ophthalmic Suspension Compared to Reference Listed Drug Azopt Brinzolamide Ophthalmic Suspension 1 in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension. | Bausch Health US, LLC | $132,500 | 6 |
| A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED, PARALLEL GROUP, MULTI-CENTER BIOEQUIVELENCE STUDY OF THE GENERIC BRINZOLAMIDE 1 OPHTHALMIC SUSPENSION COMPARED TO BRANDED BRINZOLAMIDE 1 OPHTHALMIC SUSPENSION AZOPT IN SUBJECTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION | Bausch Health US, LLC | $18,725 | 2 |
About Dr. Robert Davanzo, MD
Dr. Robert Davanzo, MD is a Ophthalmology healthcare provider based in High Point, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1558305987.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Davanzo, MD has received a total of $151,404 in payments from pharmaceutical and medical device companies, with $18,725 received in 2019. These payments were reported across 19 transactions from 6 companies. The most common payment nature is "" ($151,225).
Ad
Practice Information
- Specialty Ophthalmology
- Location High Point, NC
- Active Since 06/15/2006
- Last Updated 06/25/2009
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1558305987
Products in Payments
- BRINZOLAMIDE (Drug) $132,500
- AZOPT (Drug) $18,725
- TRAVATAN Z (Drug) $28.18
- Tecnis iTec Preloaded Delivery System (Device) $27.18
- COMBIGAN (Drug) $23.85
- BTOD (Device) $18.19
- DUREZOL (Drug) $17.96
- LUMIGAN (Drug) $17.30
- VYZULTA (Drug) $17.06
- Rhopressa (Drug) $16.01
- RESTASIS (Drug) $13.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in High Point
Sally Ong, M.d, M.D
Ophthalmology — Payments: $18,417
Ophthalmology $18,417
Yulia Radionchenko, M.d, M.D
Ophthalmology — Payments: $3,077
Ophthalmology $3,077
Michael Tepedino, Md, MD
Ophthalmology — Payments: $924.85
Ophthalmology $924.85
Kristen Godwin, Md, MD
Ophthalmology — Payments: $717.86
Ophthalmology $717.86
Dr. Michael Evans, M.d, M.D
Ophthalmology — Payments: $629.30
Ophthalmology $629.30
Dr. James Forsey, M.d, M.D
Ophthalmology — Payments: $163.86
Ophthalmology $163.86